FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a method for reducing extracellular matrix producing cells in lungs or suppressing an increase of the extracellular matrix producing cells in lungs, involving administering into an individual a composition containing (i) a carrier containing retinoid as a targeting agent, and (ii) a pro-drug specified in a group consisting of siRNA, RNA enzyme, anti-sense nucleic acid and DNA/RNA chimeric polynucleotide, which is targeted on HSP47, and vectors expressing said siRNA, RNA enzyme, anti-sense nucleic acid and/or DNA/RNA chimeric polynucleotide.
EFFECT: invention provides using retinoic acid as a targeting agent for the drug delivery to the extracellular matrix producing cells in the lungs.
8 cl, 6 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC AGENT FOR PULMONARY FIBROSIS | 2015 |
|
RU2678968C2 |
| COMPOSITION FOR RECOVERY OF NORMAL TISSUE FROM FIBROUS TISSUE | 2011 |
|
RU2650796C2 |
| AGENT FOR TREATING RENAL FIBROSIS | 2011 |
|
RU2711531C2 |
| MEANS FOR KIDNEY FIBROSIS TREATMENT | 2011 |
|
RU2635460C2 |
| AGENT FOR TREATING MYELOFIBROSIS | 2009 |
|
RU2557997C2 |
| MEANS FOR INTESTINAL FIBROSIS TREATMENT | 2012 |
|
RU2637372C2 |
| PREVENTIVE OR THERAPEUTIC AGENT FOR TREATING FIBROSIS | 2011 |
|
RU2583290C2 |
| MATERIALS AND METHODS OF TREATING CHRONIC FIBROUS DISEASES | 2006 |
|
RU2446825C2 |
| METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY FIBROUS DISEASES | 2010 |
|
RU2561672C2 |
| COMPOSITIONS AND METHODS FOR PREVENTION OR TREATMENT OF DISEASES, CONDITIONS, OR PROCESSES CHARACTERIZED BY ABERRANT FIBROBLAST PROLIFERATION AND EXTRACELLULAR MATRIX DEPOSITION | 2012 |
|
RU2620066C2 |
